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Abstract
Aims/hypothesis The main objective of this work was to
discover new drugs that can activate the differentiation of
multipotent pancreatic progenitors into endocrine cells.
Methods In vitro experiments were performed using fetal
pancreatic explants from rats and mice. In this assay, we
examined the actions on pancreatic cell development of gli-
benclamide, a sulfonylurea derivative, and glycine hydrazide
(GlyH-101), a small-molecule inhibitor of cystic fibrosis trans-
membrane conductance regulator (CFTR). We next tested the
actions of GlyH-101 on in vivo pancreatic cell development.
Results Glibenclamide (10 nmol/l–100 μmol/l) did not alter
the morphology or growth of the developing pancreas and
exerted no deleterious effects on exocrine cell development
in the pancreas. Unexpectedly, glibenclamide at its highest
concentration promoted endocrine differentiation. This
glibenclamide-induced promotion of the endocrine pathway
could not be reproduced when other sulfonylureas were
used, suggesting that glibenclamide had an off-target action.
This high concentration of glibenclamide had previously
been reported to inhibit CFTR. We found that the effects
of glibenclamide on the developing pancreas could be
mimicked both in vitro and in vivo by GlyH-101.
Conclusions/interpretation Collectively, we demonstrate
that two small-molecule inhibitors of the CFTR, glibencla-
mide and GlyH-101, increase the number of pancreatic
endocrine cells by increasing the size of the pool of neuro-
genin 3-positive endocrine progenitors in the developing
pancreas.
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KATP channel ATP-sensitive K
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Kir6.2 Inward rectifying K+ channel
NGN3 Neurogenin 3
PCSK1/3 Proprotein convertase subtilisin/kexin
type 1/3




The mature pancreas contains exocrine acinar cells that
secrete digestive enzymes into the intestine via a ductal tree,
and endocrine islets that synthesise hormones, such as insu-
lin from the beta cells, glucagon from the alpha cells, so-
matostatin from the delta cells and pancreatic polypeptide
(PP) from the PP cells. The pancreas originates from the
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dorsal and ventral regions of the foregut endoderm directly
posterior to the stomach. A hierarchy of transcription factors
regulate pancreatic specification, growth and differentiation.
First, the pancreas-committed endodermal region of the
foregut produces pancreatic and duodenal homeobox 1
(PDX1) [1]. Next, the basic helix-loop-helix transcription
factor neurogenin 3 (NGN3) initiates the endocrine differ-
entiation programme in epithelial pancreatic progenitors
[2, 3]. Subsequently, additional transcription factors deter-
mine the specific fate of the endocrine cell [4]. Such infor-
mation is crucial to develop protocols to generate in vitro
PDX1+ pancreatic progenitors from human embryonic stem
cells [5–7]. However, in vitro beta cell development from
PDX1+ pancreatic progenitors remains challenging [8]. This
is at least partly because knowledge of the signals that
regulate pancreatic endocrine cell differentiation from PDX1+
progenitors is lacking.
We recently developed a pancreatic explant assay that
can replicate pancreatic cell development from PDX1+ pro-
genitors [9], and we have previously used this assay to
define some of the factors and conditions that regulate
specific steps of pancreatic cell development [9–13]. In the
present study, we tested the effect of sulfonylurea derivatives,
such as glibenclamide, on pancreatic cell development. Sul-
fonylurea derivatives are hypoglycaemic agents that are com-
monly used to treat adults with type 2 diabetes. They restore
insulin secretion in these individuals by acting on the ATP-
sensitive K+ channel (KATP channel). The pancreatic beta cell
KATP channel is composed of four inward rectifying K
+ chan-
nel (Kir6.2) subunits, encoded by KCNJ11, and four sulfonyl-
urea receptor (SUR1) subunits encoded by ABCC8.
Sulfonylurea derivatives close the KATP channel after binding
with high affinity to the SUR1 subunits [14]. Importantly,
glibenclamide treatment has now successfully replaced insulin
injections and provides prolonged and effective glycaemic
control in newborn infants with perinatal diabetes mellitus
due to mutations in either the ABCC8 or KCNJ11 gene [15].
Using the pancreatic explant assay we established previ-
ously [9], we found that glibenclamide, even at high con-
centrations, did not have any deleterious effects on global
pancreatic development. Unexpectedly, we discovered that
high concentrations of glibenclamide increased the absolute
number of NGN3+ endocrine progenitors and the resulting
number of pancreatic beta cells. It has been reported that
high concentrations of glibenclamide can inhibit cystic
fibrosis transmembrane conductance regulator (CFTR)
[16, 17]. We found that glycine hydrazide (GlyH-101), a
small-molecule inhibitor of CFTR [18], mimicked the
effects of glibenclamide on the number of endocrine pro-
genitors and pancreatic beta cells in vitro and in vivo. In the
light of this finding, small-molecule inhibitors of the CFTR
represent new molecules to promote endocrine cell differ-
entiation in the developing pancreas.
Methods
Animals and pancreatic dissection Pregnant Wistar rats and
Swiss mice were purchased from CERJ (LeGenet, St Isle,
France). Cftr+/− mice [19] were obtained from CDTA
(Orleans, France) and were intercrossed to obtain Cftr−/−
embryos. The first day postcoitum was taken as embryonic
day (E)0.5. Dorsal pancreatic buds were dissected from
E13.5 rat and E12.5 mouse embryos using a previously
described protocol [20]. Pregnant (E12.5) mice were
injected subcutaneously twice daily for six consecutive days
with 10 mg/kg GlyH-101 (Calbiochem, Darmstadt,
Germany) or a DMSO control. All experiments were per-
formed according to the guidelines of the French Animal
Care Committee.
Organ culture Dorsal pancreases were cultured for 7 days at
37°C in a humidified 95% air–5% CO2 gas mixture on
0.45 mm filters (Millipore, St-Quentin-en-Yvelines, France) at
the air-medium interface in Petri dishes containing RPMI 1640
(Invitrogen, Saint Aubin, France) supplemented with
100 U/ml penicillin, 100 mg/ml streptomycin, 10 mmol/l
HEPES, 2 mmol/l L-glutamine, 1× non-essential amino acids
(Invitrogen) and 10% heat-inactivated fetal calf serum
(HyClone, Logan, UT, USA) [9]. Glibenclamide (MP
Biomedical, Illkirch, France) and GlyH-101 (Calbiochem)
were dissolved in DMSO (Sigma-Aldrich, Lyon, France)
and used at the required concentrations. The culture
medium was supplemented daily with glibenclamide,
GlyH-101 or DMSO. At the end of the 7 day culture
period, the pancreases were photographed and then pre-
pared for immunochemistry or RNA extraction and real-time
PCR (see below).
Immunochemistry and surface area quantification The pan-
creases were first fixed in 10% formalin, embedded in
paraffin, and then immunohistochemistry was carried out
on 4 μm-thick paraffin sections using a previously described
protocol [11]. The following primary antibodies were used at
the given dilutions: mouse anti-insulin (Sigma; 1:2,000); rab-
bit anti-glucagon (Diasorin, Antony, France; 1:1,000); rabbit
anti-amylase (Sigma; 1:300); rabbit anti-carboxypeptidase A
(CPA) (Biogenesis, Poole, UK; 1:600); rabbit anti-PDX1
([21]; 1:1,000); mouse anti-BrdU (Amersham Biosciences,
Little Chalfont, UK; 1:2); mouse anti-Ki67 (1:20; BD Phar-
mingen, Le Pont-De-Claix, France); rabbit anti-proprotein
convertase subtilisin/kexin type 1/3 (PCSK1/3) (1:100; a gift
from D.F. Steiner, University of Chicago, IL, USA); goat anti-
CFTR (1:100; Santa Cruz, Santa Cruz, CA, USA); and rabbit
anti-NGN3 ([10]; 1:1,000). The fluorescent secondary anti-
bodies were fluorescein anti-rabbit antibody (1:200) and
Texas Red anti-mouse antibody (1:200) (both from Jackson
Immunoresearch, Newmarket, UK) and fluorescein goat
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anti-rabbit Alexa Fluor 488 (1:400; Invitrogen). Nuclei were
stained with Hoechst 33342 (0.3 mg/ml; Invitrogen). NGN3
was detected using the Vectastain Elite ABC kit (Vector
Laboratories, Montrouge, France) [10].
In order to quantify the surface area of the insulin-,
glucagon-, PCSK1/3-, CPA- and amylase-producing cells
in the pancreatic explant culture, all images of all serial
sections of each pancreas were captured and digitised using
a cooled three-charge-coupled-device camera (Hamamatsu,
Middlesex, NJ, USA) attached to a fluorescence microscope
(Leitz DMRB; Leica, Rueil-Malmaison, France). The area
of each immunostain was determined in every second
section of the serially sectioned pancreases. For every
image, the areas of each immunostain were quantified using
Scanalytics IPLab image processing software (Scanalytics,
Fairfax, VA, USA). The areas of each immunostain were
then summed in order to determine the total surface area of
each cell type in each pancreas.
For mouse fetal pancreases at E18.5, insulin and gluca-
gon immunostains were quantified from eight equally sep-
arated sections. In each section, the areas of the beta and
alpha cells were determined using NIH ImageJ software
(version 1.34s, www.imagej.com-about.com/). The per-
centage surface area of the beta or alpha cells in each
pancreas was then obtained by dividing the surface area
of the insulin+ or glucagon+ cells by the surface area of
the pancreas.
In order to measure the proliferation of the early PDX1+
progenitors, we counted the frequency of BrdU+ nuclei
among 3,000 PDX1+ cells. In order to determine the abso-
lute number of NGN3+ cells in each pancreas per condition,
all pancreatic sections were first stained with the anti-NGN3
antibody. The number of NGN3+ cells was counted in each
section and then summed for each pancreas. At least three
pancreases were analysed per condition.
RNA extraction and real-time PCR Total RNA was isolated
from a pool of at least three pancreases using the
RNeasy Microkit (Qiagen, Courtaboeuf, France), and
then reverse transcribed using Superscript reagents
(Invitrogen). Real-time PCR was done with the 7300
Fast Real-time PCR system (Applied Biosystems,
Courtaboeuf, France) using a previously described proto-
col [11, 12]. Peptidylpropyl isomerase A/cyclophilin A
was used as the endogenous control gene, and E16.5
pancreatic cDNA was used as the calibrator sample.
The data were analysed by the comparative cycle thresh-
old method [22], and the results are displayed as fold
change in gene expression.
Statistical analysis All values are shown as mean±SEM; p
values were calculated using a Student’s t test; and p<0.05
was considered to be statistically significant.
Results
Glibenclamide does not alter the morphology or growth of
the developing pancreas and has no deleterious effects on
exocrine cell differentiation in the pancreas First, the effects
of glibenclamide on pancreatic morphology and growth
during development were investigated. We cultured E13.5
rat pancreases under conditions permissive for endocrine and
acinar cell development [9]. Glibenclamide (10 nmol/l–
100 μmol/l) did not modify either pancreatic morphology
(Fig. 1a) or pancreatic growth (Fig. 1b, c). As none of the
glibenclamide concentrations tested had an effect on pancre-
atic morphology or growth, glibenclamide was used at the
100 μmol/l concentration in the experiments to analyse its
effect on cell differentiation.
We next evaluated the effects of glibenclamide on exo-
crine cell development. The time-dependent induction of
amylase expression during in vitro pancreatic development
in the presence of glibenclamide was similar to that found
when developing pancreases were cultured in the absence of
glibenclamide (Fig. 1d). Moreover, the surface area of am-
ylase+ cells of the pancreases cultured for 7 days in gliben-
clamide was not different from that found in pancreases
cultured in the absence of glibenclamide (Fig. 1e, f). The
results of the analysis of the expression patterns of the two
pancreatic ductal tissue markers, Spp1 (osteopontin) and
Cftr, before and after 1, 3, 5, and 7 days of culture, indicated
that glibenclamide did not modify ductal cell development
(Fig. 1g, h).
We next defined the influence of glibenclamide on the
proliferation of PDX1+ pancreatic progenitors. We found
that glibenclamide did not modify the proportion of
PDX1+ pancreatic progenitors that incorporated BrdU
(data not shown).
Glibenclamide activates the endocrine lineage during
pancreas development In order to determine the effect of
glibenclamide on the development of endocrine progenitors,
we monitored the expression pattern of Ngn3, which enc-
odes a transcription factor that specifically labels the endo-
crine progenitors [2, 3], before and after 1, 3, 5, and 7 days
of culture in the presence or absence of glibenclamide. As
previously reported [10, 11], Ngn3 mRNA levels increased
after 1 day, peaked on day 3, and then decreased on day 7
when the pancreases were not cultured with glibenclamide
(Fig. 2a). When the pancreases were cultured with gliben-
clamide, we observed an unexpected and dramatic increase
in Ngn3 expression on culture day 5: the Ngn3mRNA levels
were sevenfold higher than those measured in the controls
(p<0.001). Thereafter, the Ngn3 mRNA levels decreased
slightly, but were still higher in the glibenclamide-treated
pancreases than in the controls (p<0.001) (Fig. 2a). This
glibenclamide-induced increase in Ngn3 mRNA level was
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paralleled by an increase in the absolute number of NGN3-
producing cells. Specifically, the number of NGN3+ cells on
day 5 was threefold higher in pancreases cultured for 5 days in
the presence of glibenclamide than in pancreases cultured for
5 days under control conditions (Fig. 2b, c). In concordance
with the glibenclamide-induced pattern of Ngn3 expression in
the developing pancreas, glibenclamide also increased the
expression of Neurod1 and Arx, encoding the transcription
factors neurogenic differentiation 1 (NEUROD1) and arista-
less related homeobox (ARX), two downstream targets of
NGN3 (Fig. 2d, e). When all these assays were done using
tolbutamide (100 μmol/l), another sulfonylurea derivative, we
found that the induction of NGN3 could not be reproduced
(data not shown).
Compared with that measured in the untreated pancreases
on culture day 7, glibenclamide caused a fourfold increase
in the expression of Pou3f4, an alpha cell-specific transcrip-
tion factor [23] (Fig. 3a). On culture day 7, glibenclamide
also significantly increased the expression of glucagon
mRNA (2.8-fold) (Fig. 3b) and somatostatin mRNA (2.2-
fold) (Fig. 3c), and induced a significant 3.5-fold increase in
the number of glucagon-producing cells (Fig. 3d, e). On the
Fig. 1 Glibenclamide does not alter the morphology and growth of the
developing pancreas and has no deleterious effects on exocrine cell
differentiation in the pancreas. (a) E13.5 rat pancreases were cultured
for 7 days without (control) or with increasing concentrations of
glibenclamide. The epithelium is shown as a dashed white line, and
is surrounded by its mesenchyme. (b) Hoechst 33342 staining of E13.5
rat pancreases cultured for 7 days with or without glibenclamide at the
two indicated concentrations. Note the lack of pycnotic nuclei in the
two glibenclamide-treated pancreases. Scale bar 50 μm. (c) The surface
area positive for Hoechst staining after 7 days of culture without or
with 10 and 100 μmol/l glibenclamide. Data are shown as mean±SEM
from five to six pancreases per condition. (d) Time-dependent changes
in amylase mRNA levels in cultured E13.5 rat pancreases before (day 0)
and after 1–7 days of culture with or without 100 μmol/l glibenclamide.
Data are shown as mean±SEM of at least three independent experiments.
(e) E13.5 rat pancreases were cultured for 7 days in the absence or
presence of 100 μmol/l glibenclamide and next analysed by immunohis-
tochemistry using anti-amylase antibodies (green). The nuclei were
stained in blue with Hoechst 33342. Scale bars 50 μm. (f) The
surface area of the amylase+ cells that developed in the presence or
absence of 100 μmol/l glibenclamide. Data are shown as mean±
SEM of three independent experiments. (g, h) Time-dependent
changes in Spp1 mRNA and Cftr mRNA levels in cultured E13.5
rat pancreases before (day 0) and after 1–7 days of culture with or
without 100 μmol/l glibenclamide. Data are shown as mean±SEM
of at least three independent experiments. In d, f–h, white bars,
without glibenclamide; black bars, with glibenclamide. D1, Day 1…D7,
Day 7; Glib, glibenclamide
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other hand, the number of insulin+ cells was substantially
lower in pancreases cultured in glibenclamide for 7 days
than in pancreases cultured for 7 days under control con-
ditions (Fig. 3f). This glibenclamide-induced reduction in
the number of insulin+ cells was accompanied by a time-
dependent decrease in the expression of insulin mRNA
(Fig. 3g). Glibenclamide is a potent insulin secretagogue
known to induce both beta cell degranulation and a sharp
decrease in insulin mRNA levels [24]. Although glibencla-
mide progressively decreased insulin gene expression on
days 0, 1, 3, 5 and 7, we found that the following were
not affected by glibenclamide over the 7 day culture period:
(1) the expression of the two beta cell-specific markers Znt8
(also known as Slc30a8) (Fig. 3h) and Mafa (Fig. 3i); and
(2) the number of cells that produced PCSK1/3, the beta
cell-specific proconvertase (Fig. 3j). From these results, we
concluded that in this first experimental setting, glibencla-
mide increased the number of endocrine progenitors, in-
creased alpha and delta cell differentiation, but did not
change the number of beta cells, as measured by Znt8 and
Mafa expression and PCSK1/3 levels, while decreasing
insulin gene expression and content.
Glibenclamide increases beta cell differentiation in the
developing pancreas We then modified the experimental
protocol in order to investigate the effect of glibenclamide
on the developing pancreas under conditions that facilitate
beta cell development using a pulse-chase approach [25].
This modified cultured protocol comprised an initial pulse
period, during which the E13.5 rat pancreases were cultured
with glibenclamide for 5 days in order to enhance NGN3
levels. This pulse period was then followed by a chase
period, during which the pancreases were cultured without
glibenclamide for 9 days. The results from pulse-chase
experiments were then compared with those obtained from
pancreases cultured without glibenclamide for 14 days.
By as early as day 2 of the chase period (day 7 of
culture), the number of insulin+ cells (Fig. 4b) and the
expression levels of insulin, Znt8 and Mafa mRNA
(Fig. 4c–e) in the glibenclamide-treated pancreases had be-
come almost identical to those found in pancreases not
treated with glibenclamide. On days 4, 6 and 9 of the chase
period (days 9, 11 and 14 of culture), the number of insulin+
cells (Fig. 4a, b), and the expression levels of insulin, Znt8,
Mafa and glucagon mRNA levels (Fig. 4c–e and data not
shown) had all increased in the glibenclamide-treated pan-
creases. Thus, exposing the developing pancreas to
100 μmol/l glibenclamide for 5 days increases the number
of NGN3+ cells that will differentiate into pancreatic endo-
crine cells during the chase period.
Inhibition of the CFTR mimics the effects of glibenclamide
on the development of pancreatic endocrine cells As it has
been reported that 100 μmol/l glibenclamide can inhibit
Fig. 2 Glibenclamide increases the number of NGN3+ endocrine
progenitors. (a) Quantification of Ngn3 transcripts in E13.5 rat
pancreases before (day 0) and after 1–7 days of culture with or
without 100 μmol/l glibenclamide. Data are shown as mean±SEM
from at least seven independent experiments; ***p<0.001. (b) Im-
munohistochemical analysis of NGN3 level in E13.5 rat pancreases
cultured for 5 days in the presence or absence of 100 μmol/l gliben-
clamide. Enlargements of sections of the image are shown alongside.
Scale bars 50 μm. (c) Number of NGN3+ cells in E13.5 pancreases
cultured for 5 days in the presence or absence of 100 μmol/l gliben-
clamide. Data are shown as mean±SEM from three independent
experiments. **p<0.01. (d, e) Time-dependent changes in the ex-
pression of Neurod1 (d) and Arx (e) mRNA in E13.5 pancreases
before (day 0), and after 1–7 days with or without 100 μmol/l gli-
benclamide. Data are shown as mean±SEM from at least seven
independent experiments; **p<0.01; ***p<0.001. White bars, with-
out glibenclamide; black bars, with glibenclamide. D1, Day 1 … D7,
Day 7; Glib, glibenclamide
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CFTR [16, 17], we speculated that glibenclamide could
induce NGN3 levels by acting on CFTR. In order to validate
this hypothesis, E13.5 rat pancreases cultured for 4 days
were first immunostained for NGN3 and CFTR. We found
that NGN3+ cells stained positive for CFTR (Fig. 5).
We then asked whether the effects of glibenclamide on
pancreatic differentiation could be reproduced using GlyH-101,
a small-molecule inhibitor of the CFTR [18]. We found
that Ngn3 expression in pancreases exposed to 10 μmol/l
GlyH-101 for 1, 3, 5 or 7 days increased at the mRNA level
(Fig. 6a) and that the absolute number of NGN3+ cells in-
creased also (Fig. 6b, c). We also found that 10 μmol/l GlyH-
101 increased the absolute number of beta cells (Fig. 6d, e)
and the expression of insulin (Fig. 6f) andMafa (Fig. 6g), but
had no effect on the proliferation of PDX1+ cells and beta cells
(data not shown). At the same time, 10 μmol/l GlyH-101 did
not influence acinar cell development (Fig. 6d).
Finally, to define whether the observed effects of GlyH-
101 were dependent on CFTR, we repeated the above-
described experiments with pancreases from Cftr−/−
embryos. We found that while 10 μmol/l GlyH-101 increased
the insulin+ area in pancreases from wild-type embryos
(electronic supplementary material [ESM] Fig. 1a), it did not
increase in pancreases from the Cftr−/− embryos (ESM
Fig. 1b). These findings strongly suggest that the effect of
GlyH-101 on beta cell development depends on CFTR. Of
note, our results also indicate that insulin+ area was increased
by 42% in cultured Cftr−/− pancreases, when compared with
control pancreases (data not shown).
GlyH-101 increases the number of endocrine cells in the
developing pancreas in vivo In order to establish whether
the in vitro effects of GlyH-101 could be reproduced in
vivo, E12.5 pregnant mice were treated twice daily with
10 mg/kg GlyH-101 for six consecutive days. At the end
of the treatment period, the fetal pancreases were dissected
from the E18.5 mouse embryos, and then prepared for
immunohistochemical analysis. GlyH-101 induced: (1) a
1.75-fold increase in the surface area of the insulin+ cells
and a twofold increase in the surface area of the glucagon+
cell in the E18.5 pancreases (p<0.01) (Fig. 7a, b); and (2)
did not modify beta cell proliferation, as measured by Ki67
immunostaining (Fig. 7a, b). Further work is needed to
define whether GlyH-101 increases the NGN3 level in vivo
as it does in vitro.
Collectively, our results indicate that two small-molecule
inhibitors of CFTR, glibenclamide and GlyH-101, can
increase the number of pancreatic endocrine cells by
Fig. 3 The in vitro effects of glibenclamide on glucagon, somatostatin
and insulin cell differentiation. (a–c) The levels of Pou3f4 mRNA (a),
glucagon mRNA (b) and somatostatin mRNA (c) in E13.5 rat pancreases
cultured for 7 days in the absence or presence of 100 μmol/l glibencla-
mide. Data are shown as mean±SEM of at least three independent
experiments; **p<0.01; ***p<0.001. (d–e) The surface area of the
glucagon+ cells in E13.5 pancreases cultured for 7 days in presence or
absence of 100 μmol/l glibenclamide. The nuclei were stained with
Hoechst 33342 fluorescent stain (blue). Data are shown as mean±SEM
of at least three independent experiments. **p<0.01. (f) Immunohisto-
chemical analysis of E13.5 rat pancreases cultured for 7 days in the
presence or absence of 100 μmol/l glibenclamide. Cell development
was evaluated using an antibody against insulin (red), and the nuclei were
stained with Hoechst 33342 fluorescent stain (blue). Scale bar 50 μm.
(g–i) Time-dependent changes in insulin (g), Znt8 (h) and Mafa (i)
mRNA levels in cultured E13.5 rat pancreases before (day 0) and after
1–7 days of culture with or without 100 μmol/l glibenclamide. Data are
shown as mean±SEMof at least six independent experiments. **p<0.01.
(j) The surface area of the PCSK1/3+ cells in the PDX-1-producing cells
that developed after 7 days of culture in the presence or absence of
100 μmol/l glibenclamide. Data are shown as mean±SEM of at least
three independent experiments. White bars, without glibenclamide; black
bars, with glibenclamide. D1, Day 1… D7, Day 7; Glib, glibenclamide

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increasing the size of the pool of NGN3+ endocrine progen-
itors in the developing pancreas.
Discussion
Here, we used an in vitro bioassay based on the culture of
E13.5 rat pancreases, in which pancreatic development from
progenitors is replicated [9]. In these fetal pancreases,
PDX1+ pancreatic progenitors first proliferate and then dif-
ferentiate into endocrine and exocrine cells [4]. Therefore,
this bioassay can be used to screen molecules and conditions
that positively or negatively regulate the proliferation and
differentiation of progenitors in the developing pancreas
[9–11, 26]. Using this assay, we found that glibenclamide
did not repress global pancreatic cell development. This
finding that glibenclamide exerts no deleterious effects on
the developing pancreas is consistent with previous reports
that, even at high concentrations, this sulfonylurea does
not induce cytotoxicity or apoptosis in a human liver
cell line [27].
An unexpected finding of this study was that the
100 μmol/l glibenclamide concentration could trigger the
endocrine differentiation pathway in the developing pancre-
as. Specifically, glibenclamide increased the number of
NGN3+ cells and the resulting number of endocrine cells.
This unexpected result suggested that glibenclamide had an
off-target effect for the following reasons: (1) NGN3 induc-
tion by glibenclamide was observed only when the drug was
used at the highest concentration, 100 μmol/l; (2) NGN3
induction could not be reproduced when tolbutamide, an-
other sulfonylurea was used instead of glibenclamide; and
Fig. 4 Glibenclamide increases pancreatic beta cell differentiation.
E13.5 rat pancreases were first cultured for 5 days with 100 μmol/
l glibenclamide (pulse period), and then for 9 days without glibencla-
mide (chase period). (a) Immunostaining of pancreatic beta cells using an
anti-insulin antibody on days 4, 6 and 9 of the chase period (red). The
nuclei were stainedwith Hoechst 33342 fluorescent stain (blue). Scale bar
50 μm. (b) Time-dependent changes in the surface area of the insulin+
cells in cultured E13.5 rat pancreases. Data are shown as mean±SEM
from at least three independent experiments. **p<0.01. (c–e)
Quantification of insulin (c), Znt8 (d) and Mafa (e) mRNA levels in
E13.5 rat pancreases cultured for 14 days without glibenclamide, or first
pulsed for 5 days with glibenclamide, then for 9 days without glibencla-
mide (chase period). Data are shown as mean±SEM from at least three
independent experiments. **p<0.01; ***p<0.001. White bars, control
pancreases cultured for 7, 9, 11 and 14 days in the absence of glibencla-
mide; black bars, pancreases cultured for 5 days in the presence of
glibenclamide (pulse period), and then for 9 days without glibenclamide
(chase period). D1, Day 1… D7, Day 7; Glib, glibenclamide
Fig. 5 CFTR+ cells produce NGN3. Immunohistochemical analyses of
E13.5 rat pancreases cultured for 4 days. The CFTR+ cells are stained
red, and the NGN3+ cells are stained brown. Scale bars 25 μm
336 Diabetologia (2013) 56:330–339
(3) the observed induction of the endocrine pathway with
glibenclamide is not consistent with direct induction of
NGN3 by glibenclamide via its target ATP-binding cassette,
sub-family C (CFTR/MRP), member 8 (ABCC8)—indeed,
NGN3 and ABCC8 are not present in the same pancreatic
compartment. Specifically, Ngn3 is expressed by endocrine
progenitors located in the pancreatic epithelial tree [2], and
ABCC8 is present in mature, terminally differentiated
endocrine cells [28]. Interestingly, it has been reported that
high concentrations of glibenclamide can inhibit CFTR
[16, 17]. In addition, CFTR and NGN3 are both produced in
the same cell type, namely the epithelial cells of the pancre-
atic ductal tree during pancreatic development.
CFTR is a chloride channel and belongs to the superfam-
ily of ATP-binding cassette transporters. ABCC8 is also a
member of this superfamily [29]. In this study, we found that
GlyH-101, a small-molecule CFTR inhibitor of the glycine
hydrazide class [18], replicates the effect of glibenclamide
on NGN3 induction in pancreatic progenitors through its
action on CFTR. By acting on ABCC8, which is located in
pancreatic beta cells, glibenclamide decreased insulin
gene expression, an effect that we did not observe when
GlyH-101 was used because GlyH-101 does not bind to
ABCC8.
Currently, defining the growth factors and small mole-
cules that increase the number of beta cells in the developing
pancreas is a major research topic in the endocrine
pancreatic field [30]. It is now established that the beta cell
mass depends on: (1) the size and the proliferative potential
of the PDX1+ progenitor pool [31, 32]; (2) the potential of
pancreatic progenitors to differentiate into beta cells; and (3)
the proliferation of terminally differentiated beta cells [33].
A number of factors have been identified that can regulate
the size of the pool of the PDX1+ cells in the developing
pancreas, such as fibroblast growth factor 10 [32] and indo-
lactam V, a non-phorbol protein kinase C activator [34].
Although numerous factors that regulate beta cell prolifera-
tion have also been identified [35], only a small number of
growth factors and small molecules have been found to
trigger beta cell differentiation from pancreatic progenitors
[11, 36]. In this study, we found that GlyH-101, a small-
molecule inhibitor of the CFTR, can increase the number of
endocrine cells in the developing pancreas. This effect was
independent of cell proliferation, as GlyH-101 modulated
neither the proliferation of PDX1+ pancreatic progenitor
cells nor beta cell proliferation. On the other hand, GlyH-
101 increased the absolute number of NGN3+ endocrine
progenitors. This effect on the number of NGN3+ cells did
not seem to be due to an increase in the proliferation of
NGN3+ cells as this cell type is poorly proliferating [37] and
did not proliferate in the experimental system we used here
[9 and data not shown].
The mechanism by which inhibition of CFTR increases
the number of endocrine cells in the developing pancreas
Fig. 6 In vitro effects of GlyH-101 on the development of pancreatic
endocrine cells. (a) Time-dependent changes in Ngn3 mRNA levels in
cultured E13.5 rat pancreases before (day 0) and after 1–7 days of
culture with or without 10 mmol/l GlyH-101. Data are shown as mean
±SEM from at least three independent experiments; **p<0.01; ***p<
0.001. (b) Immunohistochemical analysis of NGN3 level in E13.5
pancreases cultured for 5 days in the presence or absence of GlyH-
101. Scale bar 50 mm. (c) Number of NGN3+ cells in E13.5 pancreases
cultured for 5 days in presence or absence of GlyH-101. Data are
shown as mean±SEM from three independent experiments; **p<
0.01. (d) Immunostaining of E13.5 rat pancreases cultured for 5 days
in the presence or absence of GlyH-101 by anti-insulin (in red) and
anti-amylase (in green) antibodies. The nuclei were stained with
Hoechst 33342 fluorescent stain (blue). Scale bar 50 μm. (e) The
surface area of the insulin+ cells in E13.5 rat pancreases cultured for
5 days in the presence or absence of GlyH-101. Data are shown as
mean±SEM from three independent experiments; *p<0.05. (f, g)
Time-dependent changes in insulin mRNA and Mafa mRNA levels
in cultured E13.5 rat pancreases before (day 0) and after 1–7 days of
culture with or without 10 mmol/l GlyH-101. Data are shown as mean±
SEM from four independent experiments; ***p<0.001. D1, Day 1 …
D7, Day 7. White bars, without GlyH-101; black bars, with GlyH-101
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remains unknown. CFTR has many known functions. It is a
chloride channel activated by cyclic AMP and protein
kinase, and it is also permeable to large organic ions. It also
is a regulator of other ion channels. It regulates intracellular
pH, as well as cell volume [38]. Future studies are now
needed to identify those signals mediated by CFTR that
can influence the number of NGN3+ pancreatic endocrine
progenitors.
To conclude, we discovered that two small-molecule
inhibitors of the CFTR, glibenclamide and GlyH-101, can
amplify the development of pancreatic endocrine cells.
There is a major need to discover small molecules that
promote beta cell differentiation from pancreatic progenitors
[30]; our results indicate that CFTR inhibitors should be
tested in order to fulfil this still unmet need using, for
example, protocols aiming to generate, in vitro, beta cells
from PDX1+ pancreatic progenitors derived from embryonic
stem cells.
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